Plain-English translation of NCT07399067 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new injectable medication called to see if it can help people with moderate to severe atopic dermatitis (a chronic skin condition causing intense itching, redness, and inflammation). Researchers will compare at different dose levels against a placebo (a fake injection) and against , an existing treatment, to understand how well the medication works and how safe it is.
Atopic dermatitis can be severe and painful, and current topical treatments (creams and ointments) don't work well enough for many people. This trial is exploring whether this new medication could offer a better treatment option for those with moderate to severe disease.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication at one of several dose levels, an existing approved medication, or a placebo injection. You would receive shots under your skin at scheduled intervals over the study period. The study will include regular visits where your skin will be examined, your symptoms will be evaluated, and blood samples will be taken to measure how the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Enrollment target
~120 participants
Started
February 2026
Primary completion
March 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Man Yang
Innovent Biologics (Suzhou) Co. Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.